Expertise in
35
conditions

Dr. John L. Reagan

Hematology
Cancer Genetics Program Rhode Island Hospital
110 Lockwood St, 
Providence, RI 
Offers Telehealth
Expertise in
35
conditions
Cancer Genetics Program Rhode Island Hospital
110 Lockwood St, 
Providence, RI 

Overview

John Reagan is a Hematologist practicing medicine in Providence, Rhode Island.

Dr. Reagan is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 76 peer reviewed articles and participating in 4 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in RI

Hospital Affiliations

Rhode Island Hospital
Newport Hospital
Brown University Health Morton Hospital
The Miriam Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cancer Genetics Program Rhode Island Hospital
110 Lockwood St, Providence, RI 02903
Other Locations
Rhode Island Hospital
593 Eddy St, Providence, RI 02903

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: July 23, 2026
Intervention Type: Other, Drug
Study Drugs: Gemtuzumab, Donor Leukocyte Infusion
Study Phase: Phase 1/Phase 2
BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Cyclophosphamide, Dexamethasone
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

76 Total Publications

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.
Journal: Haematologica
Published: March 13, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (0.1 miles away)
401-444-5435
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Olszewski is a Hematologist practicing medicine in Providence, Rhode Island. Dr. Olszewski is highly rated in 26 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, Splenectomy, and Bone Marrow Aspiration.

Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

Frequently Asked Questions about Dr. John L. Reagan

How do I make an appointment with Dr. John L. Reagan?

You can book an appointment with Dr. John L. Reagan by calling their office at 844-222-2881. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John L. Reagan a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John L. Reagan is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John L. Reagan specialize in?

While Dr. John L. Reagan is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Multiple Myeloma, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John L. Reagan participate in research or clinical trials?

Yes. Dr. John L. Reagan has published 76 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. John L. Reagan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John L. Reagan accept my insurance?

Dr. John L. Reagan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 844-222-2881 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reagan's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile